Impact of Bariatric Surgery on Pharmacokinetic Study of Simvastatin and Carvedilol

Obesity Clinical Trial

Official title:

Impact of Roux-en-Y Gastric Bypass (RYGB) Bariatric Surgery on System Pharmacology: Single-dose Cross-over Pharmacokinetic Study of Simvastatin and Carvedilol.

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT04049786
• Other study ID #: RYGB_pk
• Status: Enrolling by invitation
• Phase: Phase 4
• Start date: June 1, 2019
• Est. completion date: August 2023

Study information

• Verified date: February 2022
• Source: Universidade Estadual Paulista Júlio de Mesquita Filho
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Obesity affects more than 1 in 3 adults in the U.S. It is commonly associated with reduced quality of life and complications such as metabolic syndrome, heart disease, high blood pressure and sleep disorders. The gastric bypass, also known as Roux-en-Y gastric bypass (RYGB), is one of the most common weight-loss surgeries due to the reliable and long-lasting weight loss and the effective remission of obesity-associated conditions. Although the impact of obesity on absorption, distribution, metabolism and excretion has been documented for several drugs, label recommendations might not account for specific population subgroups, specially morbidly obese patients and obese patients post-bariatric surgery. This study aims to investigate the impact of obesity and RYGB surgery on the kinetic disposition of simvastatin (Study A) and carvedilol (Study B).

Description:

The study is ongoing and eligible subjects are enrolled after signing a written informed consent. Research participants (n=120, in total) include healthy volunteers [body mass index (BMI) ≤ 25 kg/m2], obese [BMI > 30 kg/m2] and patients that underwent RYGB surgery 6-60 month prior this research protocol. On day 1, participants receive a single oral dose of 40 mg simvastatin (Study A) or 25 mg racemic carvedilol (Study B). Serial blood samples are collected up to 24 h for the pharmacokinetic analysis. Blood tests (blood count, fasting blood glucose, lipid profile, serum creatinine, urea, gamma-glutamyl transferase, aspartate aminotransferase and alanine amino transferase) are being monitored for all enrolled participants. Blood samples are also collected for genotyping the main genetic polymorphisms associated with carvedilol or simvastatin pharmacokinetics. Metoprolol is being used as a probe drug for CYP2D6 in vivo phenotyping only for research participants enrolled in Study B. After oral administration of metoprolol (on day 2), urine samples are being collected up to 8h after drug administration to determine the urinary metabolic ratio α-hydroxy metoprolol/metoprolol. As part of the pre-surgery evaluation (obese group) or post-surgery follow-up (RYGB group), obese patients and patients post-RYGB are submitted to digestive endoscopies. Healthy participants will not undergo endoscopic examination. The preparation protocol for digestive endoscopy includes: a) 8-hour fasting; b) 10% spray lidocaine (topical); c) oral simethicone (75 mg/ml, 80 drops); d) oxygen therapy depending on the patient (nasal catheter with O2 at 3 L/min); e) 0.02 to 0.03 mg/kg intravenous midazolam; f) 50 mg pethidine. A blood sample is collected 4-h after intravenous midazolam for in vivo CYP3A4 phenotyping. During the endoscopies, duodenum and jejunum biopsies are being collected to investigated interindividual variability related to drug oral bioavailability (only obese and post-RYGB research participants). Samples collected from digestive biopsies will be used to develop individual enteroid microfluidic systems. In vivo phenotyping of drug metabolizing enzymes and transporters will also be assessed by transcriptome using blood samples. The generated in vitro and in vivo data will be combined to build up physiologically based pharmacokinetic models for precision dosing in obese and post-RYGB patients.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 120
• Est. completion date: August 2023
• Est. primary completion date: August 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Patients of both gender with 18 to 65 years old.

• Healthy volunteers group: body mass index lower or equal to 35 kg/mˆ2.

• Obese group: body mass index higher than 30 kg/mˆ2.

• Post-RYGB group: patients previously submitted to Roux-en-Y gastric bypass bariatric surgery (6-48 months before the study).

Exclusion Criteria:

• Pregnant and lactating patients.

• Patients with serum creatinine higher than 1,5 mg/dL.

• Patients with previous altered coagulation.

• Patients with previous cancer history (on the last year).

• Patients with previous hypersensitivity history to simvastatin or carvedilol.

• Patients who were in use of any anticoagulant (heparin, low molecular weight heparin, aspirin, nonsteroidal antiinflammatory drugs).

• Patients who were in use of CYP3A4 or P-glycoprotein inhibitors or inducers.

• For carvedilol study: patients who were in use of CYP2D6 inhibitors; poor metabolizer phenotype of CYP2D6 and genotyped as CYP2C9*3/*3.

• Patients who disagree to continue the study.

Related Conditions & MeSH terms

• Bariatric Surgery
• Obesity

Intervention

Procedure:
• Digestive biopsy
All patients with indication for RYGB bariatric surgery undergo to endoscopy before and after the surgery as standard protocol. Digestive biopsy are being performed in obese and post-RYGB patients for transcriptomic analysis

Drug:
• Carvedilol 25mg
Single-dose of carvedilol 25 mg are being administrated orally.

Procedure:
• Serial blood sampling for PK analysis
Serial blood samples are being collected at times 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18 and 24 hours after drug administration for PK evaluation .

Drug:
• Metoprolol 100 mg for CYP2D6 phenotyping
Metoprolol is being used as probe drug to evaluate CYP2D6 activity. Single-dose of metoprolol 100 mg are being administrated orally.
• Simvastatin 40mg
Single-dose of simvastatin 40 mg are being administrated orally.
• Midazolam 2 mg for CYP3A4 phenotyping
Midazolam is being used as probe drug to evaluate CYP3A4 activity. Single-dose of midazolam 2 mg are being administrated intravenous.

Other:
• Genotyping
Patients are being genotyped for the main SNP on CYP2C9, ABCB1, SLCO1B1 and CYP2D6 genes using blood samples

Locations

Country	Name	City	State
United States	University of Florida	Orlando	Florida

Sponsors (3)

Lead Sponsor	Collaborator
Natalia Valadares de Moraes	Fundação de Amparo à Pesquisa do Estado de São Paulo, University of Sao Paulo

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetic analysis of simvastatin	Population pharmacokinetic modeling and simulation.	Time 0 up to 24 hours after single dose simvastatin administration.
Primary	Pharmacokinetic analysis of carvedilol	Population pharmacokinetic modeling and simulation.	From time 0 up to 24 hours after single dose carvedilol administration
Secondary	CYP2D6 phenotyping using metoprolol as a probe drug	The CYP2D6 phenotype was determined by urinary concentration ratio metoprolol/alfa-hydroxymetoprolol.	Urine sampling collected from time 0 up to 8 hours after metoprolol administration
Secondary	CYP3A4 phenotyping using midazolam as a probe drug	Midazolam plasma concentration will be determined by chromatographic analysis	Day 2: a blood sample will be collected after midazolam administration
Secondary	Genotyping the main SNPs on CYP2C9, CYP2D6, ABCB1 and SLCO1B1 genes	The main SNPs on CYP2C9, CYP2D6, ABCB1 and SLCO1B1 genes will be evaluated by RT-PCR	Day 1: a blood sample will be collected immediately after your check-in in the clinical research unit
Secondary	Transcriptomic analysis of liver extracellular vesicles	Expression levels of transporters and enzymes will be quantified by real-time quantitative PCR	Day 1: a blood sample will be collected immediately after your check-in in the clinical research unit
Secondary	Transcriptomic analysis of intestine samples	Expression levels of transporters and enzymes will be quantified by real-time quantitative PCR	Digestive biopsy collected in the second day of research protocol